Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia
Romanian journal of internal medicine = Revue roumaine de médecine interne · Temmuz 2015
YÖKSİS Kayıtları
Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia
Romanian Journal Of Internal Medicine · 2015 PUBMED, SCOPUS
PROFESÖR SÜLEYMAN BALDANE →
Makale Bilgileri
DergiRomanian journal of internal medicine = Revue roumaine de médecine interne
Yayın TarihiTemmuz 2015
Cilt / Sayfa53 · 282-285
Scopus ID2-s2.0-84956590208
Erişim🔓 Açık Erişim
Özet
Drug induced lupus erythematosus (DLE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Platelet-levels were increased and joint complaints disappeared in the first week of hydroxychloroquine and methylprednisolone treatment after chemotherapy had been discontinued. In conclusion, physicians should be alert to the possibility of DILE in patients presenting with thrombocytopenia under a capecitabine and bevacizumab chemotherapy regimen.
Yazarlar (7)
1
E. Ozaslan
2
Eray Eroglu
ORCID: 0000-0003-2571-7385
3
Kevser Gok
ORCID: 0000-0001-8639-751X
4
Soner Senel
ORCID: 0000-0002-1523-0066
5
Süleyman Baldane
6
Lutfi Akyol
7
Metin Ozkan
Metrikler
6
Atıf
7
Yazar